Business
Notice of AGM & Posting Annual Report and Accounts
Notice of AGM & Posting Annual Report and Accounts.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6200C\n N4 Pharma PLC\n 24 February 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 24 February 2022\n \n \n N4 Pharma Plc\n \n \n (\"N4 Pharma\" or the \"Company\")\n \n \n Notice of Annual General Meeting\n \n \n and\n \n \n Posting of Annual Report and Accounts\n \n \n N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting (\"AGM\"), are now available on the Company's website \n \n www.n4pharma.com\n \n \n and will be posted to shareholders today.\n \n \n The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.\n \n \n \n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n N4 Pharma Plc\n \n \n Nigel Theobald, CEO\n \n \n Luke Cairns, Executive Director\n \n \n \n \n Via IFC Advisory\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n SP Angel Corporate Finance LLP\n \n \n Nominated Adviser and Joint Broker\n \n \n Matthew Johnson/Caroline Rowe (Corporate Finance)\n \n \n Vadim Alexandre/Rob Rees (Corporate Broking)\n \n \n \n \n \n Tel: +\n \n \n 44 (0)20 3470 0470\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Turner Pope Investments (TPI) Limited\n \n \n Joint Broker\n \n \n Andy Thacker\n \n \n \n \n \n Tel: +44 (0)20 3657 0050\n \n \n \n \n \n \n IFC Advisory Limited\n \n \n Financial PR\n \n \n Graham Herring\n \n \n Zach Cohen\n \n \n \n \n Tel: +44 (0)20 3934 6630\n \n \n \n \n \n \n \n \n \n \n \n \n \n About N4 Pharma\n \n \n N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.\n \n \n N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, m...